Awareness campaign targets imaging technology for prostate Ca
Leaders from the medical, government, industry, and academic communities, among others, have unveiled a public awareness campaign to help spread the message about imaging technologies that may some day transform early detection and treatment of prostate cancer.
Leaders from the medical, government, industry, and academic communities, among others, have unveiled a public awareness campaign to help spread the message about imaging technologies that may some day transform early detection and treatment of prostate cancer.
"While women today have access to life-saving mammograms, men lack accurate, accessible, and affordable diagnostic tools. It's time men had their own 'manogram' to save lives and quality of lives," said Faina Shtern, MD, a radiologist at Children's Hospital Boston, Harvard Medical School, and president and CEO of the nonprofit AdMeTech Foundation. "Advanced imaging technologies will transform prostate cancer detection, biopsy, and treatment."
Throughout the campaign, experts will help accelerate the development and implementation of imaging technologies for improved early detection, as well as review the latest advances in patient care, research, and development.
For more information, visit www.Manogram.org.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
